Magazine article Clinical Psychiatry News

Fast-Dissolving Sumatriptan Beats Placebo for Migraine

Magazine article Clinical Psychiatry News

Fast-Dissolving Sumatriptan Beats Placebo for Migraine

Article excerpt

RANCHO MIRAGE, CALIF. -- A new rapid-release formulation of sumatriptan has proved superior to placebo at relieving migraines within 2 hours when taken early in the attack, according to the findings of a randomized, double-blind, multicenter trial.

This formulation was developed for improved gastric disintegration and dispersion in order to overcome the gastrointestinal stasis that occurs with many migraine attacks. It has been available in the United States since January. Diane Boswell said at a meeting sponsored by the Diamond Headache Clinic.

In an intention-to-treat analysis, 66% of the patients who took 100 mg of the new formulation while their pain was still mild were pain free within 2 hours, compared with 51% of patients taking a 50-mg dose and 20% of patients taking the placebo. All differences were statistically significant.

This compares favorably with the action of conventional sumatriptan tablets, said Ms. Boswell, of the department of clinical development and medical affairs at GlaxoSmithKline UK, which sponsored the study. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.